FDA seeks feedback on generative AI regulations - MedTech Dive

The MedTech Dive article reports that the FDA is seeking feedback on this discussion paper. Generative AI refers to systems capable of producing text, images, or other outputs, and in the medical device context this could cover a range of products. The device center is the FDA arm responsible for overseeing medical devices. The article does not specify which types of generative AI-enabled devices are covered or provide examples of such devices.

The discussion paper outlines a framework with three main components. Risk assessment would focus on identifying potential harms associated with a generative AI-enabled device. Premarket evaluation would address what manufacturers need to demonstrate before the device receives FDA clearance or approval. Postmarket monitoring would cover how devices perform after they reach the market. The article describes this as a potential framework, not a final regulatory proposal. The FDA has asked stakeholders for their views, though the article does not provide a deadline or a specific submission procedure. It also does not state whether the framework would apply to all generative AI-enabled devices or only certain categories, and mentions no existing devices that would be affected.

The article presents the discussion paper as an early step in the agency's effort to adapt its regulatory approach to generative AI. No timeline for finalizing the framework is reported. The article does not name any specific device or company involved. It focuses instead on the FDA's request for comments and the three areas the framework would address. The FDA's request for feedback is the only concrete action reported in the discussion paper's coverage. The discussion paper may be followed by a formal proposed rule, but the article does not say so.